Compare DDS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDS | NUVL |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 7.8B |
| IPO Year | N/A | 2021 |
| Metric | DDS | NUVL |
|---|---|---|
| Price | $569.55 | $97.48 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $519.67 | $135.33 |
| AVG Volume (30 Days) | 112.1K | ★ 441.5K |
| Earning Date | 02-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.99 | N/A |
| Revenue Next Year | $1.09 | $1,064.25 |
| P/E Ratio | $18.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $282.24 | $55.54 |
| 52 Week High | $741.98 | $113.02 |
| Indicator | DDS | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 41.83 |
| Support Level | $519.06 | $73.22 |
| Resistance Level | $634.02 | $107.13 |
| Average True Range (ATR) | 23.55 | 3.39 |
| MACD | -0.59 | -0.38 |
| Stochastic Oscillator | 5.10 | 26.94 |
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.